ipilimumab – pharmaceutical daily

September 28, 2019 Off

Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

Bristol-Myers squib’s Opdivo combined with Yervoy resulted in 52% of patients with being alive at five years, while 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free, the longest follow-up to date results for dual Immuno-Oncology (I-O) therapy in a Phase 3, randomized, controlled trial showed.

July 26, 2019 Off

Bristol-Myers Squibb study met its co-primary endpoint of overall survival with Opdivo plus low dose Yervoy

By BusinessWire

Study Met Its Co-Primary Endpoint of Overall Survival with Opdivo® (nivolumab) Plus Low Dose Yervoy® (ipilimumab) vs. Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients Whose Tumors Express PD-L1 ≥1%

October 9, 2016 Off

BMS’s lirilumab could complement nivolumab or ipilimumab?

By Dino Mustafić

Bristol-Myers Squibb Company and Innate Pharma SA today announced safety data for two Phase I studies conducted by Bristol-Myers Squibb, testing lirilumab in combination with nivolumab or ipilimumab, respectively, in patients with advanced refractory solid tumors.

October 29, 2015 Off

FDA approved BMS’s Yervoy

By Dino Mustafić

U.S. Food and Drug Administration (FDA) has approved BMS’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy.